K
Kath D. Watson
Researcher at University of Manchester
Publications - 104
Citations - 9023
Kath D. Watson is an academic researcher from University of Manchester. The author has contributed to research in topics: Rheumatoid arthritis & Rheumatology. The author has an hindex of 42, co-authored 98 publications receiving 8391 citations. Previous affiliations of Kath D. Watson include Central Manchester University Hospitals NHS Foundation Trust & Manchester Academic Health Science Centre.
Papers
More filters
Journal ArticleDOI
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
TL;DR: In patients with active RA, anti-TNF therapy was not associated with increased risk of overall serious infection compared with DMARD treatment, after adjustment for baseline risk, but the rate of serious skin and soft tissue infections was increased, suggesting an important physiologic role of TNF in host defense in the skin andsoft tissues beyond that in other tissues.
Journal ArticleDOI
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
William G Dixon,Kimme L. Hyrich,Kath D. Watson,Mark Lunt,James Galloway,Andrew Ustianowski,Deborah P M Symmons +6 more
TL;DR: The rate of TB in patients with RA treated with anti-TNF therapy was three- to fourfold higher in patients receiving INF and ADA than in those receiving ETA.
Journal ArticleDOI
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
TL;DR: Data support an improved outcome among patients receiving MTX in combination with anti-TNF-alpha therapies, and the most disabled patients were less likely to respond, despite concurrent MTX, as well as the association of smoking and poor outcome with INF.
Journal ArticleDOI
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
TL;DR: The hypothesis that the powerful antiinflammatory effect of anti–tumor necrosis α (anti-TNFα) therapy might lead to a reduction in the incidence of myocardial infarction (MI) in patients with RA is tested, and it is indicated that RA patients treated with anti-T NFα do not have a lower incidence of MI compared with RA patients treating with traditional DMARDs.
Journal ArticleDOI
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James Galloway,Kimme L. Hyrich,Louise K. Mercer,William G Dixon,Bo Fu,Andrew Ustianowski,Kath D. Watson,Mark Lunt,Deborah P M Symmons +8 more
TL;DR: In this article, the authors evaluated the risk of serious infections (SIs) in patients with RA treated with anti-TNF therapy with emphasis on the risk across different ages using data from the British Society for Rheumatology Biologics Register, a prospective observational study.